Status:
UNKNOWN
The Effect of Ketamine on Immune Function and Prognosis in Patients Undergoing Colorectal Cancer Resection
Lead Sponsor:
Yonsei University
Conditions:
Colorectal Cancer
Eligibility:
All Genders
20-80 years
Phase:
NA
Brief Summary
Systemic inflammation caused by surgery may aggravate immunosuppression in immunocompromised cancer patients. The natural killer (NK) cell is a critical part of anti-tumor immunity. ketamine, a N-meth...
Eligibility Criteria
Inclusion
- patient between 20 and 80 of age with ASA physical status Ⅰ-Ⅲ
- patient scheduled for laparoscopic colorectal cancer resection
Exclusion
- ASA physical status Ⅳ
- severe hepatorenal disease
- heart failure
- infection
- increased intracranial pressure, seizure
- preoperative chemotherapy
- immune or endocrine disease
- metastasis to other organ
- problem with communication
- pregnancy
- body mass index \> 35 kg/m2
Key Trial Info
Start Date :
September 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2020
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT03273231
Start Date
September 1 2017
End Date
July 1 2020
Last Update
January 16 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Anesthesiology and Pain Medicine, Yonsei University College of Medicine
Seoul, South Korea, 03722